EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective

Jie Chen iD, Susan Gruber iD, Hana Lee iD, Haitao Chu iD, Shiowjen Lee, Haijun Tian, Yan Wang, Weili He iD, Thomas Jemielita iD, Yang Song iD, Roy Tamura, Lu Tian und 4 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3576 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Jie Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: ECR Global, Shanghai, China. Hauptthemen laut MEDLINE: Rare Diseases, Drug Development, Orphan Drug Production. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 138 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Real‐world data (RWD) and real‐world evidence (RWE) have been increasingly used in medical product development and regulatory decision‐making, especially for rare diseases. After outlining the challenges and possible strategies to address the challenges in rare disease drug development (see the accompanying paper), the Real‐World Evidence (RWE) Scientific Working Group of the American Statistical Association Biopharmaceutical Section reviews the roles of RWD and RWE in clinical trials for drugs treating rare diseases. This paper summarizes relevant guidance documents and frameworks by selected regulatory agencies and the current practice on the use of RWD and RWE in natural history studies and the design, conduct, and analysis of rare disease clinical trials. A targeted learning roadmap for rare disease trials is described, followed by case studies on the use of RWD and RWE to support a natural history study and marketing applications in various settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesDrug DevelopmentOrphan Drug ProductionHumansResearch DesignClinical Trials as Topic

Autor:innen und Institutionen

  • ECR Global, Shanghai, China.
  • TL Revolution, Cambridge, Massachusetts, USA.
  • Pfizer Inc, Groton, Connecticut, USA.
  • US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Eli Lilly & Co., Indianapolis, Indiana, USA.
  • AbbVie, North Chicago, Illinois, USA.

ORCID-Profile: Jie Chen, Susan Gruber, Hana Lee, Haitao Chu, Weili He, Thomas Jemielita, Yang Song, Mark van der Laan, Lei Nie

Zitieren

APA

Chen, J., Gruber, S., Lee, H., Chu, H., Lee, S., Tian, H., Wang, Y., He, W., Jemielita, T., Song, Y., Tamura, R., Tian, L., Zhao, Y., Chen, Y., van der Laan, M., & Nie, L. (2025). Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3576

Vancouver

Chen J, Gruber S, Lee H, Chu H, Lee S, Tian H, et al. Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3576

BibTeX
@article{Chen2025,
  author = {Chen, Jie and Gruber, Susan and Lee, Hana and Chu, Haitao and Lee, Shiowjen and Tian, Haijun and Wang, Yan and He, Weili and Jemielita, Thomas and Song, Yang and Tamura, Roy and Tian, Lu and Zhao, Yihua and Chen, Yong and van der Laan, Mark and Nie, Lei},
  title = {Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3576}
}
Kostenlos starten →